Dr Yelena Janjigian speaks to ecancer about an update from the EDGE-Gastric trial.

This trial explores long-term outcomes of first-line therapy with domvanalimab (anti-TIGIT), zimberelimab (anti–PD-1), and FOLFOX chemotherapy in patients with advanced HER2-negative gastric (GC), gastroesophageal junction (GEJC), or oesophageal adenocarcinoma (EAC).

Dr Janjigian highlights that this combination therapy demonstrates durable responses and survival benefits for patients with advanced HER2-negative GC/GEJC/EAC, offering a promising first-line treatment strategy in this difficult-to-treat population